|
* |
Based on a multicenter, randomized, blinded trial of 1679 patients with shock who required vasopressor treatment despite fluid therapy. Patients were assigned to receive either dopamine (n=858) or norepinephrine (n=821). The primary outcome was mortality rate at day 28.7
|
|
† |
Based on a multicenter, randomized, double-blinded trial of 778 patients with shock who required vasopressor treatment despite fluid therapy and low-dose norepinephrine. Patients were assigned to receive either vasopressin (n=396) or norepinephrine (n=382). The primary outcome was mortality rate at day 28.8 |
RAAS=renin-angiotensin-aldosterone system.
|
* |
Based on a multicenter, randomized, blinded trial of 1679 patients with shock who required vasopressor treatment despite fluid therapy. Patients were assigned to receive either dopamine (n=858) or norepinephrine (n=821). The primary outcome was mortality rate at day 28.7 |
|
† |
Based on a multicenter, randomized, double-blinded trial of 778 patients with shock who required vasopressor treatment despite fluid therapy and low-dose norepinephrine. Patients were assigned to receive either vasopressin (n=396) or norepinephrine (n=382). The primary outcome was mortality rate at day 28.8 |
|
RAAS=renin-angiotensin-aldosterone system. |
|
|
References: 1. Paravati S, et al. StatPearls; 2022. Accessed January 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK507716/ 2. Demiselle J, et al. Ann Intensive Care. 2020;10(1):9. 3. Fountain JH, et al. StatPearls; 2023. Accessed January 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK470410/ 4. Bellomo R, et al. Am J Respir Crit Care Med. 2020;202(9):1253-1261. 5. VanValkinburgh D, et al. StatPearls. 2025. Accessed January 16, 2025. https://www.ncbi.nlm.nih.gov/books/NBK482411/ 6. Tibi S, et al. J Clin Med. 2023;12(14):4566. 7. De Backer D, et al. N Engl J Med. 2010;362(9):779-789. 8. Russell JA, et al. N Engl J Med. 2008;358(9):877-887. |
|
* |
Based on a multicenter, randomized, blinded trial of 1679 patients with shock who required vasopressor treatment despite fluid therapy. Patients were assigned to receive either dopamine (n=858) or norepinephrine (n=821). The primary outcome was mortality rate at day 28.7 |
|
† |
Based on a multicenter, randomized, double-blinded trial of 778 patients with shock who required vasopressor treatment despite fluid therapy and low-dose norepinephrine. Patients were assigned to receive either vasopressin (n=396) or norepinephrine (n=382). The primary outcome was mortality rate at day 28.8 |
|
RAAS=renin-angiotensin-aldosterone system. |
|
|
References: 1. Paravati S, et al. StatPearls; 2022. Accessed January 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK507716/ 2. Demiselle J, et al. Ann Intensive Care. 2020;10(1):9. 3. Fountain JH, et al. StatPearls; 2023. Accessed January 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK470410/ 4. Bellomo R, et al. Am J Respir Crit Care Med. 2020;202(9):1253-1261. 5. VanValkinburgh D, et al. StatPearls. 2025. Accessed January 16, 2025. https://www.ncbi.nlm.nih.gov/books/NBK482411/ 6. Tibi S, et al. J Clin Med. 2023;12(14):4566. 7. De Backer D, et al. N Engl J Med. 2010;362(9):779-789. 8. Russell JA, et al. N Engl J Med. 2008;358(9):877-887. |
